WHO Pharmaceuticals Newsletter 2004, No. 01
(2004; 17 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentANTIEPILEPTICS - ADR update from Australia
Afficher le documentBOTULINUM TOXIN TYPE A - Place in therapy not clearly defined
Afficher le documentCELECOXIB/ROFECOXIB - Acute temporary visual impairment
Afficher le documentDACLIZUMAB - Increased mortality in cardiac transplant patients
Afficher le documentFLUTICASONE - Update on adrenal insufficiency reports
Afficher le documentINTERFERON BETA - Safety information about risk of liver injury
Afficher le documentMETHADONE - Risk of QT prolongation
Afficher le documentMETHOTREXATE - Update on pulmonary effects
Afficher le documentMIRTAZAPINE - ADR update from Australia
Afficher le documentMORPHINE - Accidental overdose of concentrated oral solutions
Afficher le documentNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) - Postpartum administration may cause hypertension
Afficher le documentPERGOLIDE - Danger of falling asleep during daily activities
Afficher le documentPYRAZINAMIDE & RIFAMPICIN - Serious liver injury with combined use in latent tuberculosis
Afficher le documentSIBUTRAMINE - ADR update
Afficher le documentTOPIRAMATE - Warning about metabolic acidosis
Afficher le documentWARFARIN - Interaction with cranberry juice
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE
 

MIRTAZAPINE - ADR update from Australia

Australia. In the October issue of the Australian Adverse Drug Reactions Bulletin, the Australian Adverse Drug Reactions Advisory Committee (ADRAC) highlights adverse reactions associated with the antidepressant drug mirtazapine. ADRAC has received a total of 253 adverse drug reaction (ADR) reports associated with mirtazapine, including potentially serious reports of seizures (n = 16) and blood dyscrasias (15). Other mirtazapine-associated ADRs reported to ADRAC include oedema (n = 33), anxiety/agitation (24), myalgia/arthralgia (24), sedation (23) and skin reactions (20). In addition, a prescription event monitoring (PEM) study conducted in England involving over 13 000 patients found drowsiness/sedation and malaise/lassitude to be the most frequent mirtazapine-associated ADRs occurring in 5.8% and 2.8% of patients, respectively. However, although two cases of blood dyscrasias were identified in this study, there were no cases of seizures.

Reference:
Australian Adverse Drug Reactions Bulletin Vol 22, No. 5, October 2003. Available from URL: http://www.health.gov.au/tga

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013